NCT07312799Not yet recruitingPhase 1
Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322
A Two-arm, Open-label, Single-sequence, Multiple-dose Study to Evaluate the Pharmacokinetic Interaction and the Safety of AD-2321 and AD-2322 in Healthy Adult Volunteers
Source: ClinicalTrials.gov · Last updated 31 Dec 2025
Brief summary (registry, in English)
To evaluate the pharmacokinetic interactions of AD-2321, AD-2322 in healthy adult volunteers.
- Status (registry)
- Not yet recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 41 (estimated)
- First submitted
- 17 Dec 2025
- Start date
- 27 Jan 2026
- Primary completion date
- 11 Feb 2026
- Lead sponsor
- Addpharma Inc.
- Diseases
- High blood pressure
- NCT number
- NCT07312799
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 41
- From 27 Jan 2026 to the primary completion date, 11 Feb 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration
Other
- Other exclusions applied
Who the study is looking for
- Healthy adult volunteers aged ≥19 and \<65 years at the time of the screening visit
- Body weight ≥50 kg (≥45 kg for females) and body mass index (BMI) between 18.0 kg/m² and 30.0 kg/m² at the time of the screening visit
Age in the registry: 19 years to 64 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| H+ Yangji Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.